Piramal Pharma FY2026 results: ₹8,869 cr revenue

What Piramal Pharma announced

Piramal Pharma Limited informed stock exchanges about its financial results for the year ended March 31, 2026, along with a set of governance and leadership updates. The disclosures covered both standalone and consolidated performance for FY2026. Alongside the numbers, the company confirmed board-level re-appointments and changes in key managerial personnel. It also disclosed an updated registered office address in Mumbai with an effective date at the end of April 2026. These updates matter because they combine full-year financial outcomes with decisions on who will steer strategy and compliance over the next few years. The announcements were carried through exchange filings, cited as sourced from BSE and also reflected across exchange intimations. The company is listed on NSE under the symbol PPLPHARMA and on BSE with scrip code 543635.

FY2026 revenue: standalone versus consolidated

For FY2026, Piramal Pharma reported standalone revenue of ₹4,782.01 crore. On a consolidated basis, revenue was higher at ₹8,869.08 crore for the same period ended March 31, 2026. The gap between standalone and consolidated figures reflects the larger group footprint captured in consolidated reporting. While the filing highlights revenue totals, it does not provide a segment split in the provided text. Investors typically track both sets of numbers because standalone performance can indicate the health of the core entity, while consolidated results capture subsidiaries and group-level impacts. In regulated industries like pharmaceuticals, consolidated results can also reflect acquisitions, overseas operations, and one-off items more visibly than standalone accounts. The FY2026 revenue figures were released alongside audited results processes scheduled through a board meeting.

Profit and loss: PAT on standalone, loss on consolidated

Piramal Pharma reported a standalone profit after tax (PAT) of ₹700.01 crore in FY2026. This was compared with ₹691.40 crore in the previous year, indicating a modest year-on-year improvement at the standalone level based on the figures disclosed. On a consolidated basis, however, the company reported a net loss after tax of ₹325.94 crore for FY2026. The text links the consolidated loss to “operational and exceptional items,” including an impairment charge recognised during the year. This split outcome underscores why investors often read consolidated statements closely, particularly when exceptional items affect headline profitability. The disclosure does not provide further detail on other exceptional items beyond the impairment charge mentioned.

Impairment charge highlighted in FY2026

A key exceptional item referenced in the disclosure is an impairment charge of ₹175.82 crore recognised during the year. Impairment charges typically reflect a reassessment of asset values, which can reduce reported profits without being a cash expense in the same period. In Piramal Pharma’s case, the impairment is explicitly cited as a significant component among the items affecting consolidated performance. The filing excerpt does not specify which asset or business line the impairment relates to. It also does not quantify the full set of exceptional items beyond the impairment figure provided. Even so, highlighting impairment in the result narrative signals its relevance to understanding why consolidated earnings differ from the standalone profit picture.

Board-approved leadership re-appointments

Alongside financial results, Piramal Pharma disclosed a set of board decisions on leadership continuity. Ms. Nandini Piramal was re-appointed as Whole-Time Director and designated as Executive Director and Chairperson for a further term of three years starting April 1, 2027. The company also stated that Mr. Peter DeYoung was re-appointed as Whole-Time Director, designated as Executive Director, for a three-year term effective October 6, 2026. These re-appointments provide clarity on board-level leadership tenure and the scheduled start dates of the renewed terms. Such disclosures are material under listing regulations because they establish decision-making continuity at the top of the organisation. The text provided does not mention any change in responsibilities beyond the stated designations.

Independent director terms and earlier board change

The board also approved re-appointments of Independent Directors Mr. Sridhar Gorthi and Mr. Peter Stevenson for a second term of five consecutive years, effective March 30, 2027. Separately, exchange information in the provided text notes that Mr. Subramanian Ramadorai ceased as an Independent Director with effect from February 9, 2026, with a related intimation referencing completion of his term. Together, these updates show a mix of continuity and rotation in independent director positions. The disclosure does not provide reasons beyond term completion, nor does it discuss any committee changes. For investors, independent director appointments are monitored for governance continuity and compliance with board composition norms.

Company secretary transition and compliance oversight

Piramal Pharma announced a transition in key managerial personnel with the appointment of Mr. Maneesh Sharma as Company Secretary and Compliance Officer effective April 29, 2026. He is set to take over from Ms. Pratibha Mishra, who served as the interim lead as per the disclosure. The company’s exchange communication on the board meeting and conference call was signed by Pratibha Mishra as Interim Company Secretary and digitally submitted on April 17, 2026. The timing aligns with the results cycle and scheduled investor interactions, where the company secretary function typically supports regulatory filings and disclosures. The update provides a clear effective date but does not include the outgoing or incoming officer’s tenure details beyond the interim reference.

Registered office address update effective April 30, 2026

The company disclosed that it has updated its registered office address in Mumbai, with the change taking effect on April 30, 2026. The new location is stated as the Ananta Building, Piramal Corporate Park. Registered office changes are routine but material from a statutory standpoint because they affect official correspondence and regulatory records. The text does not provide the previous Mumbai registered office address in the excerpt, but it clearly states the effective date and the new site. For stakeholders, such updates are relevant for legal notices and documentation.

Board meeting, trading window, and earnings call schedule

Piramal Pharma’s exchange intimation stated that the board meeting was scheduled for April 28, 2026 to consider and approve the audited financial results, both standalone and consolidated, for the quarter and year ended March 31, 2026. The disclosure also stated that the trading window for dealing in the company’s securities was closed from April 1, 2026 to April 30, 2026, inclusive of both dates, in connection with the results process. In addition, the company planned an earnings conference call on April 29, 2026 from 9:30 AM to 10:15 AM IST to discuss Q4 and full-year FY2026 results with investors and analysts. The conference call included global dial-in access and specified India dial-in numbers and toll-free options for India, the US, and the UK in the provided text. The stated purpose and timeline align with standard disclosure practice under SEBI listing regulations, with the intimation referencing Regulation 29 compliance.

Key numbers and dates at a glance

Why the update matters for investors and compliance tracking

The FY2026 disclosure presents a split picture where standalone profitability contrasts with a consolidated loss, with impairment explicitly flagged as one of the notable items. For investors, this reinforces the need to track consolidated exceptional items when evaluating full-group performance. The governance decisions also set a timeline for leadership continuity, with re-appointments taking effect across late 2026 and 2027, rather than immediately. The appointment of a new Company Secretary and Compliance Officer effective April 29, 2026 is also relevant for disclosure execution and ongoing compliance, particularly around the results cycle. Finally, the board meeting, trading window closure, and earnings call details are practical inputs for market participants who track event-driven timelines and information access.

Closing note

Piramal Pharma’s FY2026 communication combined audited financial outcomes, a stated impairment charge impacting consolidated results, and a series of board and management updates with defined effective dates. The next immediate milestone in the disclosed schedule was the earnings conference call on April 29, 2026, following the board meeting on April 28, 2026, as per the exchange intimation.